David G. Maloney

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.

D. Maloney, T. Davis, S. Dowden, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma

D. Maloney, J. Pagel, T. Gooley, 2007, Bone Marrow Transplantation.

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

D. Maloney, W. Velasquez, R. Dillman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical status and optimal use of rituximab for B-cell lymphomas.

D. Maloney, P. Mclaughlin, C. White, 1998, Oncology.

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.

M. Lunning, E. Purev, M. Palomba, 2023, Blood.

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

S. de Vos, C. Jacobson, S. Neelapu, 2023, Blood.

Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.

D. Maloney, O. Press, Oliver W. Press, 1998, Oncology.